文献速递淋巴瘤

来那度胺/利妥昔单抗在未经治疗滤泡性淋巴瘤中诱导高度分子学缓解:LYSA RELEVANCE辅助研究

Lenalidomide/rituximab induces high molecular response in untreated follicular lymphoma: LYSA ancillary RELEVANCE study.
PubMed 文献 · Blood Adv · 2020-01-01

RELEVANCE是首个比较无化疗方案来那度胺/利妥昔单抗(R2)与利妥昔单抗/化疗(R-Chemo)一线治疗初治滤泡性淋巴瘤(FL)的3期试验。本辅助研究分析440例法国患者中222例可检测BCL2-JH易位者,第24周时外周血和骨髓完全分子学缓解(CMR)率分别为98%和78%,R2组CMR率(90%)高于R-Chemo组(77%)(P=.022),CMR与更优无进展生存(PFS)相关。

要点

  • 第24周外周血CMR率98%,骨髓CMR率78%。
  • R2组CMR率90%(105/117)高于R-Chemo组77%(70/90)(P=.022)。
  • CMR患者3年PFS 84%,可检测MRD患者55%(P=.015)。

核心结论

  • 与RELEVANCE试验临床结果一致,R2免疫调节一线治疗FL可获得高比例CMR。

研究设计与样本

  • RELEVANCE为3期试验(NCT01650701),比较R2与R-Chemo一线治疗初治FL。
  • LYSA RELEVANCE MRD研究纳入440例法国患者,分析其中222例诊断时BIOMED-2可检测BCL2-JH易位者。
  • 采用微滴数字聚合酶链反应定量MRD,灵敏度≤10⁻⁴。

主要发现

  • 第24周(诱导治疗结束)外周血CMR率98%,骨髓CMR率78%。
  • CMR(外周血和/或骨髓)患者3年PFS 84%,可检测MRD患者55%(P=.015)。
  • R2组CMR率90%(105/117)高于R-Chemo组77%(70/90)(P=.022)。
  • 分子病持续存在对PFS的不良预后价值与治疗组无关(交互作用检验P=.31)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Complete molecular response (CMR) after first-line immunochemotherapy reflects treatment efficacy and may predict prognosis in patients with follicular lymphoma (FL). RELEVANCE is the first phase 3 trial comparing the chemotherapy-free regimen lenalidomide/rituximab (R2) vs rituximab/chemotherapy (R-Chemo) in previously untreated FL patients (ClinicalTrials.gov identifier: NCT01650701). The objective of the minimal residual disease (MRD) analysis was to determine the ability of a chemotherapy-free regimen to induce CMR. Of 440 French patients participating in the Lymphoma Study Association (LYSA) RELEVANCE MRD study, all 222 patients with a BIOMED-2-detectable BCL2-JH translocation at diagnosis were analyzed. MRD was quantified by droplet digital polymerase chain reaction with a sensitivity ≤10-4. At week 24 (end of induction treatment), 98% and 78% of patients achieved CMR in peripheral blood (PB) and bone marrow (BM), respectively. Achievement of CMR (in PB and/or BM) had a significant impact on progression-free survival (PFS), with 3-year PFS of 84% and 55% for patients with CMR and detectable MRD, respectively (P = .015). CMR at week 24 was reached more frequently in the R2 arm (105/117; 90%) than in the R-Chemo arm (70/90; 77%) (P = .022). The poor prognostic value in terms of PFS for the persistence of molecular disease was observed irrespective of treatment arm (interaction test, P = .31). In agreement with the clinical results of the RELEVANCE trial, our results show that R2 immunomodulatory treatment in first-line FL can achieve high rates of CMR.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Delfau-Larue MH, Boulland ML, Beldi-Ferchiou A, et al. Lenalidomide/rituximab induces high molecular response in untreated follicular lymphoma: LYSA ancillary RELEVANCE study. Blood Adv. 2020. PMID: 32673385. doi:10.1182/bloodadvances.2020001955

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。